醫學研究中人工智慧倫理準則發布
New guidelines released for AI ethics in medical research
Updated at: September 21, 2026 at 12:30 AM
截至2026年9月，人工智慧與醫學研究的交叉領域正在經歷重大轉變。
As of September 2026, the intersection of artificial intelligence and medical research is undergoing a major shift.
世界衛生組織（WHO）發布了一份名為《人工智慧相關健康研究：倫理審查與監督》的新報告，旨在為研究人員和倫理委員會提供實用指導。
The World Health Organization (WHO) has released a new report, 'Artificial Intelligence-related Health Research: Ethics Review and Oversight,' aiming to provide practical guidance for researchers and ethics committees.
這項倡議解決了倫理監督中的關鍵缺口，重點關注演算法偏誤、知情同意，以及在低收入環境中使用人工智慧的特定挑戰。
This initiative addresses a critical gap in ethical oversight, focusing on algorithmic bias, informed consent, and the specific challenges of AI use in low-income settings.
除了世界衛生組織外，國家機構和主要期刊也正採取行動。
Beyond the WHO, national bodies and major journals are also taking action.
例如，科學技術部針對醫學影像研究引進了「生命週期」方法，而《美國醫學會雜誌》（JAMA）現在要求嚴格披露人工智慧的使用情況，並禁止在同儕審查中使用人工智慧工具，以確保資料隱私。
For instance, the Ministry of Science and Technology has introduced a lifecycle approach to medical imaging research, while JAMA now mandates strict disclosure of AI usage and prohibits the use of AI tools for peer review to ensure data privacy.
這些發展反映了全球邁向「生命週期治理」的趨勢，從單純的檢查清單轉向人工智慧模型部署後的持續監控。
These developments reflect a global move toward 'lifecycle governance,' moving away from simple checklists toward continuous monitoring of AI models after deployment.
儘管國際政策仍面臨一些碎片化現象，但其核心使命明確：確保人工智慧始終是輔助而非取代人類判斷的工具，同時優先考量公平性、透明度以及對敏感健康資料的保護。
While international policies still face some fragmentation, the core mission is clear: ensuring that AI remains a tool that supports, rather than replaces, human judgment, while prioritizing fairness, transparency, and the protection of sensitive health data.
